Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

In the ENESTnd study, with≥ 10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …

With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …

Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with
Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and/or …

Early successes in identifying and targeting individual oncogenic drivers, together with the
increasing feasibility of sequencing tumor genomes, have brought forth the promise of …

The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15
cases/106/year without any major geographic or ethnic differences [1]. The median age at …